Lanzatech Global, Inc. · NASDAQ:LNZA
Lanzatech Global — Investor Presentation (January 2025)
10 slides from Lanzatech Global's investor presentation, January 2025
Slide 1: LanzaX Dedicated Strain Innovation
LanzaX Dedicated Strain Innovation Accelerating the path to scale and commercialization of globally sought-after synthetic biology strains + Nasdaq: LNZA
Slide 2: Disclaimer
DISCLAIMER This presentation includes forward-looking statements regarding, among other things, the plans, strategies, and prospects, both business and financial, of LanzaTech. These statements are based on the beliefs, assumptions, projections and conclusions of LanzaTech’s management. Forward-look
Slide 3: LanzaX: A Commercial Launchpad for Sustainable Chemical Production
LanzaX A Commercial Launchpad for Sustainable Chemical Production LanzaTech intends to spin out its synthetic biology and strain engineering platform into a growth-oriented joint venture to access capital needed to accelerate its existing development pipeline of projects, including acetone, isopropa
Slide 4: Symbiotic Relationship with LanzaTech
LanzaX Symbiotic Relationship with LanzaTech LanzaX is designed to take the reins on existing and future research and development projects, enabling LanzaTech to focus on high-impact commercial growth priorities of its core biorefining platform, including increasing opportunities in sustainable avia
Slide 5: Compelling Total Addressable Market Spanning Multiple Verticals
LanzaX Compelling Total Addressable Market Spanning Multiple Verticals LanzaX has the potential to be a transformational biomanufacturing platform that leverages dedicated capital and a team with deep expertise to fast track the development of an existing portfolio of near-commercial molecules in bi
Slide 6: Revenue Model – Driving Profitable Growth
LanzaX Revenue Model – Driving Profitable Growth CUSTOMERS Value proposition: CUSTOMERS Global brands, Value proposition: Provide specialized Value creation from Industrial Government product sales while partners, heavy Agencies, and Universities research and microbe off-takes LanzaX reducing emissi
Slide 7: Competitive Edge: Uniquely Positioned Over Competitors
LanzaX Competitive Edge Uniquely Positioned Over Competitors Most advanced synthetic biology platform for C1 microbes and partnership with LanzaTech provides powerful path to scale Capabilities: Service Model Organism Portfolio Biofoundry Gas Handling Scale Up Proven path to LanzaX Yes C1 Microbes Y
Slide 8: Capabilities
LanzaX Capabilities ✓ Leading synthetic biology platform for C1 microbes ✓ State-of-the art strain modeling, AI, and synthetic biology capabilities across full design-build-test-learn cycle ✓ Building on 15+ years of genetic tool development and optimization of continuous, gas fermentation organisms
Slide 9: Team
LanzaX Team ▪ LanzaTech to transfer over 30 talented and experienced employees to LanzaX: → Aggregate years of experience: 250+ Search to commence for new CEO CEO of LanzaX → Number of doctorates: 10+ PhD (Molecular Biology, Microbiology, Biotechnology, Bioengineering, Chemical Engineering, Computat
Slide 10: Investor contact
Investor contact: Kate Walsh VP Investor Relations [email protected]
LanzaTech Global — Investor Presentation (January 2025) on 6ix